JP2019507180A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507180A5 JP2019507180A5 JP2018546596A JP2018546596A JP2019507180A5 JP 2019507180 A5 JP2019507180 A5 JP 2019507180A5 JP 2018546596 A JP2018546596 A JP 2018546596A JP 2018546596 A JP2018546596 A JP 2018546596A JP 2019507180 A5 JP2019507180 A5 JP 2019507180A5
- Authority
- JP
- Japan
- Prior art keywords
- adjuvant
- seq
- composition
- optionally
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022027569A JP7417645B2 (ja) | 2016-03-04 | 2022-02-25 | がんに対する組合せ療法 |
| JP2024000506A JP7785817B2 (ja) | 2016-03-04 | 2024-01-05 | がんに対する組合せ療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1603805.1 | 2016-03-04 | ||
| GBGB1603805.1A GB201603805D0 (en) | 2016-03-04 | 2016-03-04 | Combination |
| GBGB1610018.2A GB201610018D0 (en) | 2016-06-08 | 2016-06-08 | Combination |
| GB1610018.2 | 2016-06-08 | ||
| PCT/EP2017/055093 WO2017149150A1 (en) | 2016-03-04 | 2017-03-03 | Combination therapy against cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022027569A Division JP7417645B2 (ja) | 2016-03-04 | 2022-02-25 | がんに対する組合せ療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019507180A JP2019507180A (ja) | 2019-03-14 |
| JP2019507180A5 true JP2019507180A5 (https=) | 2020-04-09 |
Family
ID=58231605
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546596A Pending JP2019507180A (ja) | 2016-03-04 | 2017-03-03 | がんに対する組合せ療法 |
| JP2022027569A Active JP7417645B2 (ja) | 2016-03-04 | 2022-02-25 | がんに対する組合せ療法 |
| JP2024000506A Active JP7785817B2 (ja) | 2016-03-04 | 2024-01-05 | がんに対する組合せ療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022027569A Active JP7417645B2 (ja) | 2016-03-04 | 2022-02-25 | がんに対する組合せ療法 |
| JP2024000506A Active JP7785817B2 (ja) | 2016-03-04 | 2024-01-05 | がんに対する組合せ療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190343940A1 (https=) |
| EP (2) | EP3423087B1 (https=) |
| JP (3) | JP2019507180A (https=) |
| DK (1) | DK3423087T3 (https=) |
| ES (1) | ES2965009T3 (https=) |
| FI (1) | FI3423087T3 (https=) |
| HR (1) | HRP20240052T1 (https=) |
| HU (1) | HUE064857T2 (https=) |
| LT (1) | LT3423087T (https=) |
| PL (1) | PL3423087T3 (https=) |
| PT (1) | PT3423087T (https=) |
| SI (1) | SI3423087T1 (https=) |
| WO (1) | WO2017149150A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53355A (fr) | 2015-05-29 | 2022-03-16 | Agenus Inc | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
| US10273281B2 (en) | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| HRP20240052T1 (hr) * | 2016-03-04 | 2024-03-29 | Io Biotech Aps | Kombinirana terapija protiv raka |
| JP7066696B2 (ja) | 2016-10-11 | 2022-05-13 | アジェナス インコーポレイテッド | 抗ｌａｇ－３抗体及びその使用方法 |
| DK3551660T5 (da) | 2016-12-07 | 2024-09-02 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| KR20190139216A (ko) | 2017-04-28 | 2019-12-17 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법 |
| US11306144B2 (en) | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
| WO2019102265A1 (en) * | 2017-11-23 | 2019-05-31 | Theraphage Inc. | Peptide displaying bacteriophage nanoparticles and related compositions and methods |
| US20200299401A1 (en) * | 2017-11-24 | 2020-09-24 | Io Biotech Aps | Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc) |
| BR112020016986A2 (pt) | 2018-02-21 | 2021-03-02 | Five Prime Therapeutics, Inc. | formulações de anticorpo contra b7-h4 |
| KR20200144094A (ko) | 2018-03-02 | 2020-12-28 | 파이브 프라임 테라퓨틱스, 인크. | B7-h4 항체 및 이의 사용 방법 |
| GB201818576D0 (en) * | 2018-11-14 | 2018-12-26 | Io Biotech Aps | Arginase 2 polypeptides |
| US12589132B2 (en) | 2019-02-22 | 2026-03-31 | Five Prime Therapeutics, Inc. | CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors |
| KR102653960B1 (ko) * | 2020-07-23 | 2024-04-03 | 의료법인 성광의료재단 | 암 치료를 위한 면역체크포인트 억제제의 병용 요법 |
| MX2023010371A (es) | 2021-03-05 | 2024-02-12 | Univ Basel | Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb. |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| GB202103673D0 (en) * | 2021-03-17 | 2021-04-28 | Io Biotech Aps | Combination therapy for cancer |
| EP4340948A4 (en) * | 2021-05-17 | 2025-03-12 | Wisconsin Alumni Research Foundation (WARF) | SYNTHETIC PROTEIN TO INDUCE IMMUNE TOLERANCE |
| US20250213664A1 (en) * | 2022-02-18 | 2025-07-03 | Modernatx, Inc. | Mrnas encoding checkpoint cancer vaccines and uses thereof |
| US20250327041A1 (en) | 2022-02-24 | 2025-10-23 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| WO2026008017A1 (en) * | 2024-07-03 | 2026-01-08 | Everest Medicines (China) Co., Ltd. | Cancer vaccines and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| WO2008100562A2 (en) * | 2007-02-14 | 2008-08-21 | Medical College Of Georgia Research Institute, Inc. | Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells |
| EP3320912B1 (en) | 2008-04-17 | 2021-03-31 | IO BIOTECH ApS | Indoleamine 2, 3-dioxygenase based immunotherapy |
| EP4079319A1 (en) | 2011-10-17 | 2022-10-26 | IO Biotech ApS | Pd-l1 based immunotherapy |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| SG11201606428UA (en) * | 2014-02-04 | 2016-09-29 | Incyte Corp | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
| JP6652557B2 (ja) * | 2014-05-30 | 2020-02-26 | ヴェンタナ メディカル システムズ， インク． | Ｐｄ−ｌ１について染色された腫瘍組織の改善されたスコア化のための多重アッセイ |
| HRP20240052T1 (hr) * | 2016-03-04 | 2024-03-29 | Io Biotech Aps | Kombinirana terapija protiv raka |
-
2017
- 2017-03-03 HR HRP20240052TT patent/HRP20240052T1/hr unknown
- 2017-03-03 LT LTEPPCT/EP2017/055093T patent/LT3423087T/lt unknown
- 2017-03-03 DK DK17709038.8T patent/DK3423087T3/da active
- 2017-03-03 JP JP2018546596A patent/JP2019507180A/ja active Pending
- 2017-03-03 HU HUE17709038A patent/HUE064857T2/hu unknown
- 2017-03-03 FI FIEP17709038.8T patent/FI3423087T3/fi active
- 2017-03-03 SI SI201731444T patent/SI3423087T1/sl unknown
- 2017-03-03 ES ES17709038T patent/ES2965009T3/es active Active
- 2017-03-03 EP EP17709038.8A patent/EP3423087B1/en active Active
- 2017-03-03 PT PT177090388T patent/PT3423087T/pt unknown
- 2017-03-03 WO PCT/EP2017/055093 patent/WO2017149150A1/en not_active Ceased
- 2017-03-03 EP EP23202447.1A patent/EP4316517A3/en active Pending
- 2017-03-03 US US16/081,778 patent/US20190343940A1/en not_active Abandoned
- 2017-03-03 PL PL17709038.8T patent/PL3423087T3/pl unknown
-
2021
- 2021-09-07 US US17/468,263 patent/US20220257741A1/en active Pending
-
2022
- 2022-02-25 JP JP2022027569A patent/JP7417645B2/ja active Active
-
2024
- 2024-01-05 JP JP2024000506A patent/JP7785817B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507180A5 (https=) | ||
| JP2019508444A5 (https=) | ||
| JP2016531907A5 (https=) | ||
| IL268620B2 (en) | Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment | |
| JP2018501197A5 (https=) | ||
| FI3429618T3 (fi) | Immuunijäjestelmän tarkistuspisteen modulaattorin ja soluun tunkeutuvan peptidin, cargon ja tlr-peptidiagonistin kompleksin yhdistelmä lääketieteelliseen käyttöön | |
| IL277188B2 (en) | Intracellular delivery of biomolecules to modify the immune response | |
| JP2019514393A5 (https=) | ||
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| RU2017117596A (ru) | Связывающие молекулы, специфичные в отношении CD73, и пути их применения | |
| RU2016107426A (ru) | Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета | |
| HRP20230512T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma | |
| JP2018509163A5 (https=) | ||
| JP2020512973A5 (https=) | ||
| Ahmad et al. | PD-L1-specific T cells | |
| JP7267014B2 (ja) | 癌ワクチンにおける使用のためのｐｄｌ１ペプチド | |
| AU2021341521A1 (en) | Heterologous prime boost vaccine | |
| Emerson et al. | Overcoming tumor-induced immune suppression: from relieving inhibition to providing costimulation with T cell agonists | |
| JP2019516768A5 (https=) | ||
| CN117500830A (zh) | 治疗中针对cd40和cd137的多特异性结合剂 | |
| JP2019505210A5 (https=) | ||
| RU2020110148A (ru) | Противораковые вакцины | |
| HRP20211754T1 (hr) | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova | |
| AU2022360108A1 (en) | Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers | |
| JPWO2019245038A5 (https=) |